Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

BridgeBio Pharma (BBIO) Interest Expenses (2019 - 2025)

BridgeBio Pharma's Interest Expenses history spans 7 years, with the latest figure at -$38.4 million for Q4 2025.

  • For Q4 2025, Interest Expenses fell 278.49% year-over-year to -$38.4 million; the TTM value through Dec 2025 reached $53.1 million, down 41.64%, while the annual FY2025 figure was $53.1 million, 41.64% down from the prior year.
  • Interest Expenses for Q4 2025 was -$38.4 million at BridgeBio Pharma, down from $11.7 million in the prior quarter.
  • Across five years, Interest Expenses topped out at $42.1 million in Q1 2025 and bottomed at -$38.4 million in Q4 2025.
  • The 5-year median for Interest Expenses is $20.3 million (2022), against an average of $17.6 million.
  • The largest annual shift saw Interest Expenses soared 142.84% in 2021 before it tumbled 278.49% in 2025.
  • A 5-year view of Interest Expenses shows it stood at $15.1 million in 2021, then skyrocketed by 32.09% to $20.0 million in 2022, then rose by 1.39% to $20.3 million in 2023, then rose by 6.19% to $21.5 million in 2024, then crashed by 278.49% to -$38.4 million in 2025.
  • Per Business Quant, the three most recent readings for BBIO's Interest Expenses are -$38.4 million (Q4 2025), $11.7 million (Q3 2025), and $37.6 million (Q2 2025).